Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease (CKD) Sub-study to Protocol Number 1308084213
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- The percent change in the bone marrow lipid fraction averaged between L2, L3 and L4 at baseline to 12 months and 12 months to 24 months.
研究概览
简要总结
Chronic Kidney Disease (CKD) is associated with bone changes and very high fracture rates. A component of bone is marrow. Bone marrow fat is increased in patients with CKD compared to those in the normal population of the same age. It is not clear if there will be changes in the marrow fact content in those with CKD on Pioglitazone. In people with normal kidney function, thiazolidinedione group of drugs have had variable effects on bone marrow fat content, as measured by MRS. This is important as changes in marrow fat are likely related to changes in the bone in patients with chronic kidney disease.
详细描述
If patients consent to participate in the ancillary study of marrow fat changes with pioglitazone, those that are randomized to placebo or 15 mg pioglitazone for 12 months (per the criteria in the main study) will also undergo magnetic resonance spectroscopy (MRS) of the lumbar spine at L1, L2 and L3. MR spectroscopy of the lumbar spine (if they choose as this is ancillary study) will be performed 3 times over the course of the study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Included subjects will be those who consent to the study of Pioglitazone in ADPKD (Protocol number 1308084213). Therefore inclusion and exclusion criteria are the same as for that study. Subjects will NOT be offered participation in the bone marrow fat study till after they consent for the FDA approved study. Subjects who withdraw from the FDA approved study will be withdrawn from this protocol.
- •Inclusion/Exclusion Criteria for NCT#02697617
- •Male or female ADPKD patients aged 18-55
- •eGFR at or above ≥ 50 ml/min/1.73 m2 by 4 parameter MDRD or CKD-Epiformulas
- •normal liver enzymes (ALT/AST)
- •fasting blood glucose between 70 and120
- •for female patients, a willingness to use double contraception to avoid pregnancy while in study
- •able to give informed consent
- •In the opinion of the investigator, high likelihood of progressive kidney disease
排除标准
- •diabetes, defined as any of the following: fasting blood sugar > 130 times two, HgbA1C > 7, on any blood sugar lowering medication, or past diagnosis of diabetes not occurring during pregnancy
- •uncontrolled hypertension, defined as systolic > 150, diastolic > 90 despite an attempt by physician to titrate medications
- •history of impaired systolic function (ejection fraction < 50%) by previous ECHO or known ischemic cardiovascular disease
- •findings suggestive of a kidney disease other than ADPKD
- •systemic illness requiring immunosuppressive or anti-inflammatory agents
- •congenital absence of a kidney or history of a total nephrectomy
- •history of cyst reduction or partial nephrectomy
- •history of renal cyst aspiration within the previous year
- •History of bladder cancer, or gross hematuria
- •inability to undergo MRI due to implantable devices or foreign objects that preclude MRI
- •active renal transplant
- •allergy or sensitivity to any of the components of the test materials
- •institutionalized
- •currently pregnant or plans to become pregnant during the study
结局指标
主要结局
The percent change in the bone marrow lipid fraction averaged between L2, L3 and L4 at baseline to 12 months and 12 months to 24 months.
时间窗: Baseline, 12 months, 24 months
Subjects will undergo and MRI at Baseline, 12 months, and 24 months to measure bone marrow.
次要结局
未报告次要终点
研究者
Ranjani Moorthi
Assistant Professor, Division of Nephrology
Indiana University